Cross-reactive Antibody Response to mRNA SARS-CoV-2 Vaccine After Recent COVID-19-Specific Monoclonal Antibody Therapy

Cross-reactive Antibody Response to mRNA SARS-CoV-2 Vaccine After Recent COVID-19-Specific Monoclonal Antibody Therapy

Abstract The efficacy of coronavirus disease 2019 (COVID-19) vaccines administered after COVID-19-specific monoclonal antibody is unknown, and “antibody interference” might hinder immune responses leading to vaccine failure. In an institutional review board–approved prospective study, we found that...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Open Forum Infectious Diseases 2021-09, Vol.8 (9), p.ofab420-ofab420
Hauptverfasser: Schultz-Cherry, Stacey, McGargill, Maureen A, Thomas, Paul G, Estepp, Jeremie H, Gaur, Aditya H, Allen, E Kaitlynn, Allison, Kim J, Tang, Li, Webby, Richard J, Cherry, Sean D, Lin, Chun-Yang, Fabrizio, Thomas, Tuomanen, Elaine I, Wolf, Joshua
Format: Artikel
Sprache:eng
Schlagworte:
Biopharmaceutics
Brief Reports
Coronaviruses
Health aspects
Immune response
Messenger RNA
Monoclonal antibodies
Vaccination
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract The efficacy of coronavirus disease 2019 (COVID-19) vaccines administered after COVID-19-specific monoclonal antibody is unknown, and “antibody interference” might hinder immune responses leading to vaccine failure. In an institutional review board–approved prospective study, we found that an individual who received mRNA COVID-19 vaccination
ISSN:2328-8957
2328-8957
DOI:10.1093/ofid/ofab420